Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation.

摘要: Objective We evaluated whether a discriminant model of prediction based on quantitative distribution panel biomolecules in maternal serum can discriminate normal pregnancies from those who will develop preeclampsia (PE) prior to onset clinical symptoms at 11–15 weeks' gestation. Methods Case control study encompassing 56 women destined PE cases matched 1:3 for gestational age with 168 controls. After multiple median (MoM) conversion all available markers, comprising total Activin A (t-activin A), P-selectin, and vascular endothelial growth factor receptor (VEGFR) the combined likelihood ratios generated each marker were used calculate, patient enrolled study, odds being affected given positive results (OAPR) developing PE. For analyses performed, type II error was < 20% I fixed 5%. Results Data expressed MoM P-selectin identified as best ability between controls PE, followed by A). No significant differences VEGFR observed By using 3% prevalence (or, about 1:33) we found that OAPR 1:9 or 10% (1:1–1:417). The 1:40 2.5% (range, 1:6–1:4205). Detection rate statistical model, 5% false-positive 59%. Conclusion This analysis revealed markers assessed first second trimester pregnancy asymptomatic patients improve early detection higher risk Copyright © 2007 John Wiley & Sons, Ltd.